Comparison of tadalafil and sildenafil in controlling neonatal persistent pulmonary hypertension.
Comparison of tadalafil and sildenafil in controlling neonatal persistent pulmonary hypertension.
复制标题
他达拉非与西地那非控制新生儿持续性肺动脉高压的比较
DOI：
10.5812/ijp.6385
复制
发表时间：
2016
影响因子：
0.5
通讯作者：
Mohammadtaghi Sarebanhassanabadi
中科院分区：
文献类型：
--
作者：
M. Alipour;M. Lookzadeh;S. Namayandeh;Zohreh Pezeshkpour;Mohammadtaghi Sarebanhassanabadi
背景：新生儿持续性肺动脉高压（PPHN）常见于产后新生儿，发病率为1 / 500 - 1500。对患有PPHN的婴儿进行常规治疗后，生存率约为69%。体外膜氧合（ECMO）治疗可提高生存率达86%。方法：对32例PPHN患儿进行研究。这些新生儿被随机分为两个16例组：A组给予他达拉非，B组给予西地那非。研究对象的选择采用简单随机抽样的方法。治疗前后6个月采用超声心动图评估三尖瓣反流严重程度（TR）、肺动脉主干（MPA）直径、平均肺动脉压（MPAP）、右心室舒张末期内径（RVEDD）。结果：两组治疗后MPAP均降低，但两组平均变化量无显著差异（P = 0.48）。他达拉非和西地那非均显著降低了TR严重程度、RVEDD和MPA直径（P < 0.05），但两组TR、RVEDD和MPA变化的平均值相似（P = 0.05）。结论：他达拉非和西地那非可以相似地降低MPAP、TR严重程度、RVEDD和MPA直径。
Background: Persistent pulmonary hypertension of the newborn (PPHN) occurs in post-term neonates with an incidence of 1 in 500 - 1,500 live births. The survival rate is approximately 69% after conventional management of infants suffering from PPHN. Ex-tracorporeal membrane oxygenation (ECMO) therapy improves survival up to 86%. Methods: A total of 32 neonates with PPHN participated in this study. These neonates were randomly assigned into two 16-case groups: group A received tadalafil while group B received sildenafil. A random simple sampling method was used for the selection of subjects. The severity of tricuspid regurgitation (TR), main pulmonary artery (MPA) diameter, mean pulmonary artery pressure (MPAP), and right ventricular end-diastolic diameter (RVEDD) were assessed by echocardiography before and 6 months after treatment. Results: MPAP decreased after treatment in both groups, but the mean of changes in PAP in the two groups was not significantly different (P = 0.48). Both tadalafil and sildenafil significantly reduced the TR severity, RVEDD, and MPA diameter (P < 0.05), but the mean of the changes in TR, RVEDD, and MPA in both groups was similar (P = 0.05). Conclusions: Tadalafil and sildenafil can similarly reduce MPAP, TR severity, RVEDD, and MPA diameter.
非先天性心脏病相关的小儿肺动脉高压。
影响因子：
0.9
作者：
Ivy,DD;Feinstein,JA;Humpl,T;Rosenzweig,EB
通讯作者：
Rosenzweig,EB